Coronary atherosclerotic plaque intervention with Tongxinluo capsule (TXL-CAP): a multicenter, randomized, double-blind and placebo-controlled study.

ABSTRACT: Clinical evidence of traditional Chinese medicine Tongxinluo capsule therapy on coronary plaque vulnerability is lacking. To investigate whether Tongxinluo may increase coronary plaque stability in patients admitted with acute coronary syndrome based on statin therapy, the TXL-CAP study, a multicenter, randomized, double-blind clinical trial, was conducted. Patients who had a coronary thin-cap lipid-rich plaque detected by optical coherence tomography (OCT) were randomized 1:1 to either Tongxinluo or placebo treatment for 12 months on the basis of guideline-directed treatment. The primary endpoint was the difference in the minimum fibrous cap thickness of the OCT-assessed lesions between Tongxinluo and placebo groups in patients at the end of 12 months. A total of 220 patients were finally

SUBMITTER: Ni M 

PROVIDER: S-EPMC12932843 | biostudies-literature | 2026 Feb

REPOSITORIES: biostudies-literature